GoAI
Get started
Tempus AI, Inc. logo

Tempus AI, Inc.

TEM

NASDAQHealthcareMedical - Healthcare Information Services

Open in GoAI

Regular session

$67.0797

−$5.6103 · -7.72%

Aug 24, 2:00 PM ET

TEM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

72

Undervalued

Momentum

48

Neutral

Sentiment

47

Mixed

Risk resilience

18

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Eric Lefkofsky
Listed since
Jun 14, 2024
Employees
3,800

Market position

Day range

Current $67.0797

52-week range

Current $67.0797

Open
$69.82
Previous close
$72.69
Volume
7.44M
1.15× average
Average volume
6.49M
Average daily volume
Market cap
11.75B USD
Beta
3.58
Market reference 1
50-day average
$52.6604
+27.38% above average
200-day average
$56.7758
+18.15% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
11.01B USD
P/E (TTM)
-46.91×
P/B (TTM)
27.12×
P/S (TTM)
8.21×
EV / EBITDA
-92.93×
Earnings yield
-2.38%
Free cash flow yield
-2.38%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
63.98%
Operating margin
-19.76%
Net margin
-17.77%
Return on equity
-49.87%
Return on assets
-10.77%
Return on invested capital
-10.90%

Financial health

Debt / equity
3.25×
Current ratio
3.13×
Altman Z-score
2.98
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends79%13%-52%-118%Gross margin, FY2021: 32.44%Gross margin, FY2022: 40.60%Gross margin, FY2023: 53.81%Gross margin, FY2024: 54.96%Gross margin, FY2025: 62.74%Operating margin, FY2021: -94.52%Operating margin, FY2022: -82.78%Operating margin, FY2023: -36.87%Operating margin, FY2024: -99.67%Operating margin, FY2025: -19.88%Net margin, FY2021: -100.52%Net margin, FY2022: -90.38%Net margin, FY2023: -40.26%Net margin, FY2024: -101.79%Net margin, FY2025: -19.27%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 32.44%. Gross margin FY2022 40.60%. Gross margin FY2023 53.81%. Gross margin FY2024 54.96%. Gross margin FY2025 62.74%. Operating margin FY2021 -94.52%. Operating margin FY2022 -82.78%. Operating margin FY2023 -36.87%. Operating margin FY2024 -99.67%. Operating margin FY2025 -19.88%. Net margin FY2021 -100.52%. Net margin FY2022 -90.38%. Net margin FY2023 -40.26%. Net margin FY2024 -101.79%. Net margin FY2025 -19.27%.

Income trends

Revenue

1.27B USD+83.41%

Operating income

−252.87M USD+63.41%

Net income

−245.03M USD+65.28%
Income trends across reported periods1.47B USD678.51M USD−112.53M USD−903.57M USDRevenue, FY2021: 257.85M USDRevenue, FY2022: 320.67M USDRevenue, FY2023: 531.82M USDRevenue, FY2024: 693.4M USDRevenue, FY2025: 1.27B USDOperating income, FY2021: −243.71M USDOperating income, FY2022: −265.44M USDOperating income, FY2023: −196.08M USDOperating income, FY2024: −691.08M USDOperating income, FY2025: −252.87M USDNet income, FY2021: −259.19M USDNet income, FY2022: −289.81M USDNet income, FY2023: −214.12M USDNet income, FY2024: −705.81M USDNet income, FY2025: −245.03M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 257.85M USD. Revenue FY2022 320.67M USD. Revenue FY2023 531.82M USD. Revenue FY2024 693.4M USD. Revenue FY2025 1.27B USD. Operating income FY2021 −243.71M USD. Operating income FY2022 −265.44M USD. Operating income FY2023 −196.08M USD. Operating income FY2024 −691.08M USD. Operating income FY2025 −252.87M USD. Net income FY2021 −259.19M USD. Net income FY2022 −289.81M USD. Net income FY2023 −214.12M USD. Net income FY2024 −705.81M USD. Net income FY2025 −245.03M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.27B USD693.4M USD531.82M USD320.67M USD257.85M USD
Cost of goods sold473.89M USD312.29M USD245.65M USD190.48M USD174.21M USD
Gross profit797.9M USD381.11M USD286.18M USD130.19M USD83.64M USD
Research and development319.03M USD316.84M USD185.5M USD162.25M USD128.35M USD
Selling, general, and administrative715.43M USD755.35M USD296.76M USD233.38M USD199M USD
Operating expenses1.05B USD1.07B USD482.26M USD395.63M USD327.36M USD
Interest income12.63M USD11.08M USD7.6M USD3.03M USD623K USD
Interest expense70.27M USD53.65M USD46.87M USD21.89M USD15.18M USD
Depreciation and amortization102.32M USD37.25M USD33.33M USD30.41M USD23.88M USD
Operating income−252.87M USD−691.08M USD−196.08M USD−265.44M USD−243.71M USD
Net income−245.03M USD−705.81M USD−214.12M USD−289.81M USD−259.19M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.41
FY2025
Latest fiscal-year revenue
1.27B USD
FY2025 · +83.41% year over year
Next fiscal-year EPS consensus
-0.21
FY2026 · 9 analysts
Next fiscal-year revenue consensus
1.6B USD
FY2026 · 13 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend2.29-0.21-2.72-5.23FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend2.78B1.87B946.97M28.15MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$59.40

11.45% downside
Past 12 months12-month forecastHigh $70.00Average $59.40Low $50.00

Recent analyst actions

12 institutions
TD CowenmaintainBuy

TEM news

zacks.com

Best-Performing Leveraged ETF Areas of Last Week

These leveraged ETFs surged last week as biotech, AI, crypto and Bitcoin-linked stocks rallied despite rising Treasury yields.

Read source
businesswire.com

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software…

Read source
fool.com

Why Tempus AI Skyrocketed This Week

Tempus AI stock surged this week after Merck and Moderna published encouraging trial results for a cancer treatment. A company that Tempus AI is acquiring provided technologies that aided the development of Merck and…

Read source
seekingalpha.com

Tempus AI: Winning With Precision Medicine

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance…

Read source
fool.com

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

The transaction involved 3,000 shares with a value of $161,700 on August 14. The sale reduced West's direct equity position by 8%.

Read source
fool.com

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

Polovin executed the sale of 30,075 shares between August 18 and August 19, generating approximately $1.5 million in proceeds. The transaction was non-discretionary and performed to satisfy statutory tax withholding…

Read source

TEM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.91

+0.36%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.41

+0.20%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$549.02

+0.18%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.28

-0.67%

Sanofi logo

SNY

Sanofi

$45.63

-0.48%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$826.32

-0.93%

ETFs holding TEM

Funds reporting this stock among their holdings, ordered by reported position size.

ARK Innovation ETF logoARK Innovation ETFARKK
Market value
443.27M
Weight
6.68%
AUM
5.56B USD
Expense ratio
0.75%
Price / 1D
$84.24-2.28%
ARK Genomic Revolution ETF logoARK Genomic Revolution ETFARKG
Market value
180.74M
Weight
8.72%
AUM
1.56B USD
Expense ratio
0.75%
Price / 1D
$47.875-3.19%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
158.53M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.96-0.34%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
114.4M
Weight
0.06%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$302.29-0.81%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
66.25M
Weight
0.15%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$353.78-1.36%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
57.15M
Weight
0.54%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$212.21-0.63%
JPMorgan U.S. Tech Leaders ETF logoJPMorgan U.S. Tech Leaders ETFJTEK
Market value
52.51M
Weight
1.18%
AUM
4.46B USD
Expense ratio
0.65%
Price / 1D
$98.07-1.91%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
52.03M
Weight
0.05%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.11-0.99%

Continue in GoAI

Research TEM

research.disclaimer